These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 21059804)

  • 1. Prostaglandin E2 differentially modulates human platelet function through the prostanoid EP2 and EP3 receptors.
    Petrucci G; De Cristofaro R; Rutella S; Ranelletti FO; Pocaterra D; Lancellotti S; Habib A; Patrono C; Rocca B
    J Pharmacol Exp Ther; 2011 Feb; 336(2):391-402. PubMed ID: 21059804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PGE(2) reverses G(s)-mediated inhibition of platelet aggregation by interaction with EP3 receptors, but adds to non-G(s)-mediated inhibition of platelet aggregation by interaction with EP4 receptors.
    Glenn JR; White AE; Iyu D; Heptinstall S
    Platelets; 2012; 23(5):344-51. PubMed ID: 22436052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of prostanoid receptors in mediating the effects of PGE(2) on human platelet function.
    Iyú D; Glenn JR; White AE; Johnson AJ; Fox SC; Heptinstall S
    Platelets; 2010; 21(5):329-42. PubMed ID: 20433310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PGE1 and PGE2 modify platelet function through different prostanoid receptors.
    Iyú D; Jüttner M; Glenn JR; White AE; Johnson AJ; Fox SC; Heptinstall S
    Prostaglandins Other Lipid Mediat; 2011 Feb; 94(1-2):9-16. PubMed ID: 21095237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DG-041 inhibits the EP3 prostanoid receptor--a new target for inhibition of platelet function in atherothrombotic disease.
    Heptinstall S; Espinosa DI; Manolopoulos P; Glenn JR; White AE; Johnson A; Dovlatova N; Fox SC; May JA; Hermann D; Magnusson O; Stefansson K; Hartman D; Gurney M
    Platelets; 2008 Dec; 19(8):605-13. PubMed ID: 19012178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
    Pampuch A; Cerletti C; de Gaetano G
    Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective activation of the prostaglandin E2 receptor subtype EP2 or EP4 leads to inhibition of platelet aggregation.
    Kuriyama S; Kashiwagi H; Yuhki K; Kojima F; Yamada T; Fujino T; Hara A; Takayama K; Maruyama T; Yoshida A; Narumiya S; Ushikubi F
    Thromb Haemost; 2010 Oct; 104(4):796-803. PubMed ID: 20664890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostaglandin E2 promotes wound-induced migration of intestinal subepithelial myofibroblasts via EP2, EP3, and EP4 prostanoid receptor activation.
    Iwanaga K; Okada M; Murata T; Hori M; Ozaki H
    J Pharmacol Exp Ther; 2012 Mar; 340(3):604-11. PubMed ID: 22138372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationships between optical aggregometry (type born) and flow cytometry in evaluating ADP-induced platelet activation.
    Sbrana S; Della Pina F; Rizza A; Buffa M; De Filippis R; Gianetti J; Clerico A
    Cytometry B Clin Cytom; 2008 Jan; 74(1):30-9. PubMed ID: 17630652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation.
    Meja KK; Barnes PJ; Giembycz MA
    Br J Pharmacol; 1997 Sep; 122(1):149-57. PubMed ID: 9298541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation.
    Philipose S; Konya V; Sreckovic I; Marsche G; Lippe IT; Peskar BA; Heinemann A; Schuligoi R
    Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2416-23. PubMed ID: 21071691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doubling the clopidogrel dose in patients with reduced responsiveness to the standard dose is associated with a limited effectiveness as evaluated by impedance aggregometry.
    Stellbaum C; Ayral Y; Morguet A; Schultheiss HP; Rauch U
    Cardiovasc Revasc Med; 2012; 13(3):159-66. PubMed ID: 22503564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
    Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
    Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reciprocal regulation of human platelet function by endogenous prostanoids and through multiple prostanoid receptors.
    Hubertus K; Mischnik M; Timmer J; Herterich S; Mark R; Moulard M; Walter U; Geiger J
    Eur J Pharmacol; 2014 Oct; 740():15-27. PubMed ID: 25003953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. E-prostanoid (EP)2/EP4 receptor-dependent maturation of human monocyte-derived dendritic cells and induction of helper T2 polarization.
    Kubo S; Takahashi HK; Takei M; Iwagaki H; Yoshino T; Tanaka N; Mori S; Nishibori M
    J Pharmacol Exp Ther; 2004 Jun; 309(3):1213-20. PubMed ID: 14872092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo intra-luteal implants of prostaglandin (PG) E1 or E2 (PGE1, PGE2) prevent luteolysis in cows. II: mRNA for PGF2α, EP1, EP2, EP3 (A-D), EP3A, EP3B, EP3C, EP3D, and EP4 prostanoid receptors in luteal tissue.
    Weems YS; Bridges PJ; Jeoung M; Arreguin-Arevalo JA; Nett TM; Vann RC; Ford SP; Lewis AW; Neuendorff DA; Welsh TH; Randel RD; Weems CW
    Prostaglandins Other Lipid Mediat; 2012 Jan; 97(1-2):60-5. PubMed ID: 22120546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of aggregation and inhibition of adenylate cyclase in human platelets by prostaglandin E analogues.
    Matthews JS; Jones RL
    Br J Pharmacol; 1993 Feb; 108(2):363-9. PubMed ID: 8448586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulation of renin release by prostaglandin E2 is mediated by EP2 and EP4 receptors in mouse kidneys.
    Schweda F; Klar J; Narumiya S; Nüsing RM; Kurtz A
    Am J Physiol Renal Physiol; 2004 Sep; 287(3):F427-33. PubMed ID: 15113745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased VASP phosphorylation in platelets of male and female smokers of young age.
    Assinger A; Schmid W; Volf I
    Platelets; 2010; 21(8):596-603. PubMed ID: 20822337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel.
    Bal Dit Sollier C; Berge N; Boval B; Dubar M; Drouet L
    Thromb Haemost; 2010 Sep; 104(3):571-81. PubMed ID: 20664906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.